Dobney Hypertension Centre, School of Biomedical Science - Royal Perth Hospital Unit, University of Western Australia, Crawley, WA 6009, Australia.
Dobney Hypertension Centre, School of Medicine - Royal Perth Hospital Unit, University of Western Australia, Crawley, WA 6009, Australia.
Biosci Rep. 2021 May 28;41(5). doi: 10.1042/BSR20210029.
In this review, we focus specifically on the role that the metalloproteinase, A Disintegrin and Metalloproteinase 17 [ADAM17] plays in the development and progression of the metabolic syndrome. There is a well-recognised link between the ADAM17 substrate tumour necrosis factor α (TNF-α) and obesity, inflammation and diabetes. In addition, knocking out ADAM17 in mice leads to an extremely lean phenotype. Importantly, ADAM17-deficient mice exhibit one of the most pronounced examples of hypermetabolism in rodents to date. It is vital to further understand the mechanistic role that ADAM17 plays in the metabolic syndrome. Such studies will demonstrate that ADAM17 is a valuable therapeutic target to treat obesity and diabetes.
在这篇综述中，我们特别关注金属蛋白酶 A 去整合素和金属蛋白酶 17（ADAM17）在代谢综合征的发展和进展中所起的作用。ADAM17 的底物肿瘤坏死因子 α（TNF-α）与肥胖、炎症和糖尿病之间存在着众所周知的联系。此外，在小鼠中敲除 ADAM17 会导致其表现出极度消瘦的表型。重要的是，ADAM17 缺陷型小鼠表现出迄今为止啮齿动物中代谢最为明显的例子。进一步了解 ADAM17 在代谢综合征中的作用的机制至关重要。这些研究将表明 ADAM17 是治疗肥胖和糖尿病的有价值的治疗靶点。
